Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2023 | The potential of BTKIs in multiple sclerosis

Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses a new class of molecules with great potential to address unmet needs in multiple sclerosis (MS) clinical care, the Bruton’s tyrosine kinase inhibitors (BTKIs). BTKIs target both the adaptive and innate immune systems, which underlie various aspects of the MS pathophysiology. It is, therefore, expected that their efficacy extends from relapsing to progressive MS. Moreover, in contrast to current disease-modifying treatments, BTKIs may provide therapeutic benefits without causing prolonged B-cell depletion and thus may not harbor the same risks with chronic use. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


G. Comi has received consulting and speaking fees from Novartis, Sanofi Genzyme, Genzyme Corporation, Merck KGgA, Merck Serono SpA, Celgene Group, Bristol-Myers Squibb, Janssen, F. Hoffman-La Roche, Almirall SpA